Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Henry Schein (HSIC) Stock Price

Media headlines about Henry Schein (NASDAQ:HSIC) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Henry Schein earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.9393050036889 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news stories that may have effected Accern Sentiment’s rankings:

Henry Schein (NASDAQ:HSIC) traded up $1.34 during midday trading on Friday, reaching $75.96. The company’s stock had a trading volume of 1,146,820 shares, compared to its average volume of 1,680,000. The company has a current ratio of 1.55, a quick ratio of 0.86 and a debt-to-equity ratio of 0.30. The firm has a market cap of $12,140.00, a P/E ratio of 21.89, a PEG ratio of 1.91 and a beta of 0.99. Henry Schein has a 12-month low of $65.28 and a 12-month high of $93.50.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.87 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.90 by ($0.03). The company had revenue of $3.16 billion for the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. Henry Schein’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.84 EPS. research analysts forecast that Henry Schein will post 3.6 earnings per share for the current fiscal year.

A number of equities research analysts have weighed in on HSIC shares. Robert W. Baird set a $95.00 price target on shares of Henry Schein and gave the company a “buy” rating in a report on Thursday, October 19th. Zacks Investment Research downgraded shares of Henry Schein from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Stifel Nicolaus cut their price target on shares of Henry Schein from $89.00 to $77.00 and set a “hold” rating for the company in a report on Tuesday, November 7th. Craig Hallum raised shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Tuesday, November 7th. Finally, Evercore ISI started coverage on shares of Henry Schein in a report on Thursday, January 4th. They issued an “outperform” rating and a $81.00 price target for the company. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $84.23.

In other Henry Schein news, Director Barry J. Alperin sold 5,796 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the sale, the director now owns 48,172 shares in the company, valued at approximately $3,408,650.72. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.19% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Henry Schein (HSIC) Stock Price” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Insider Buying and Selling by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with's FREE daily email newsletter.

Leave a Reply